Enhanced primary tumor delineation in pancreatic adenocarcinoma using ultrasmall super paramagnetic iron oxide nanoparticle-ferumoxytol: An initial experience with histopathologic correlation

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 1891-1896

  Hedgire, Sandeep S ^a   Mino Kenudson, Mari ^a   Elmi, Azadeh ^a   Thayer, Sarah ^a   Fernandez del Castillo, Carlos ^a   Harisinghani, Mukesh G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Borderline resectable pancreatic cancer; Neoadjuvant therapy; Pancreatic cancer; Tumor margin

Indexed keywords

CAPECITABINE; FERUMOXYTOL; NANOPARTICLE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; CONTRAST MEDIUM; MAGNETITE; MAGNETITE NANOPARTICLE;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; FIBROSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGING SYSTEM; INFLAMMATION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; PREOPERATIVE CARE; QUANTITATIVE ANALYSIS; RADIATION DOSE; ADENOCARCINOMA; CHEMISTRY; COMPARATIVE STUDY; IMAGE ENHANCEMENT; PANCREAS TUMOR; PATHOLOGY; PILOT STUDY; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STATISTICS; SYNTHESIS;

ADENOCARCINOMA; AGED; CONTRAST MEDIA; FEMALE; FERROSOFERRIC OXIDE; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MALE; PANCREATIC NEOPLASMS; PILOT PROJECTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STATISTICS AS TOPIC;

EID: 84899148220     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S59788     Document Type: Article

References (32)

1. Saif MW. Advancements in the management of pancreatic cancer: 2013. JOP J Pancreas. 2013;14(2):112-118.
2. Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg. 1997;225(5):621-633; discussion 633-636.
3. American Cancer Society. Cancer Facts and Figures 2013. Atlanta: American Cancer Society; 2013. Available at: http://www.cancer.org/cancer/pancreaticcancer/detailedguide/pancreatic-cancer-key-statistics. Accessed February 18, 2014.
4. Garcea G, Dennison AR, Pattenden CJ, Neal CP, Sutton CD, Berry DP. Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. JOP J Pancreas. 2008;9(2):99-132.
5. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17):1605-1617.
6. Tempero MA, Arnoletti JP, Behrman SW, et al. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Cancer Netw JNCCN. 2012;10(6):703-713.
7. Cooper AB, Tzeng CW, Katz MH. Treatment of borderline resectable pancreatic cancer. Curr Treat Options Oncol. 2013;14(3):293-310.
8. Iyer R. Radiation injury: imaging findings in the chest, abdomen and pelvis after therapeutic radiation. Cancer Imaging. 2006;6:S131-S139.
9. Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys. 1995;31(5):1237-1248.
10. Erkan M, Reiser-Erkan C, Michalski CW, et al. The impact of the activated stroma on pancreatic ductal adenocarcinoma biology and therapy resistance. Curr Mol Med. 2012;12(3):288-303.
11. De Gaetano AM, Rufini V, Castaldi P, et al. Clinical applications of (18)F-FDG PET in the management of hepatobiliary and pancreatic tumors. Abdom Imaging. 2012;37(6):983-1003.
12. Michl P, Gress TM. Current concepts and novel targets in advanced pancreatic cancer. Gut. 2013;62(2):317-326.
13. Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009;16(7):1727-1733.
14. Horton KM, Fishman EK. Adenocarcinoma of the pancreas: CT imaging. Radiol Clin North Am. 2002;40(6):1263-1272.
15. Klauss M, Schöbinger M, Wolf I, et al. Value of three-dimensional reconstructions in pancreatic carcinoma using multidetector CT: initial results. World J Gastroenterol. 2009;15(46):5827-5832.
16. Ichikawa T, Haradome H, Hachiya J, et al. Pancreatic ductal adenocarcinoma: preoperative assessment with helical CT versus dynamic MR imaging. Radiology. 1997;202(3):655-662.
17. Schima W, Ba-Ssalamah A, Goetzinger P, Scharitzer M, Koelblinger C. State-of-the-art magnetic resonance imaging of pancreatic cancer. Top Magn Reson Imaging. 2007;18(6):421-429.
18. Katz MHG, Fleming JB, Bhosale P, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118(23):5749-5756.
19. Krishnamoorthy SK, Hayim M, Vestal T, Saif MW. Highlights on novel imaging methods of pancreatic cancer. JOP J Pancreas. 2013;14(4): 388-390.
20. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2000;4(6):567-579.
21. Howard TJ, Krug JE, Yu J, et al. A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon's contribution to long-term survival in pancreatic cancer. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2006;10(10):1338-1345; discussion 1345-1346.
22. Harisinghani M, Ross RW, Guimaraes AR, Weissleder R. Utility of a new bolus-injectable nanoparticle for clinical cancer staging. Neoplasia. 2007;9(12):1160-1165.
23. Saokar A, Islam T, Jantsch M, Saksena MA, Hahn PF, Harisinghani MG. Detection of lymph nodes in pelvic malignancies with Computed Tomography and Magnetic Resonance Imaging. Clin Imaging. 2010;34(5):361-366.
24. Lu M, Cohen MH, Rieves D, Pazdur R. FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol. 2010;85(5):315-319.
25. Alam SR, Shah ASV, Richards J, et al. Ultrasmall superparamagnetic particles of iron oxide in patients with acute myocardial infarction: early clinical experience. Circ Cardiovasc Imaging. 2012;5(5):559-565.
26. Farrell BT, Hamilton BE, Dósa E, et al. Using iron oxide nanoparticles to diagnose CNS inflammatory diseases and PCNSL. Neurology. 2013;81(3):256-263.
27. Kakite S, Fujii S, Nakamatsu S, et al. Usefulness of administration of SPIO prior to RF ablation for evaluation of the therapeutic effect: an experimental study using miniature pigs. Eur J Radiol. 2011;78(2): 282-286.
28. Koda M, Tokunaga S, Miyoshi K, et al. Assessment of ablative margin by unenhanced magnetic resonance imaging after radiofrequency ablation for hepatocellular carcinoma. Eur J Radiol. 2012;81(10):2730-2736.
29. Mori K, Fukuda K, Asaoka H, et al. Radiofrequency ablation of the liver: determination of ablative margin at MR imaging with impaired clearance of ferucarbotran-feasibility study. Radiology. 2009;251(2):557-565.
30. Muldoon LL, Gahramanov S, Li X, Marshall DJ, Kraemer DF, Neuwelt EA. Dynamic magnetic resonance imaging assessment of vascular targeting agent effects in rat intracerebral tumor models. Neuro Oncol. 2010;13(1):51-60.
31. Kievit FM, Stephen ZR, Veiseh O, et al. Targeting of primary breast cancers and metastases in a transgenic mouse model using rationally designed multifunctional SPIONs. ACS Nano. 2012;6(3):2591-2601.
32. Ryschich E, Schmidt J, Loeffler T, et al. Different radiogenic effects on microcirculation in healthy pancreas and in pancreatic carcinoma of the rat. Ann Surg. 2003;237(4):515-521.